Susvimo™ (ranibizumab) – New drug approval
October 22, 2021 - Genentech announced the FDA approval of Susvimo (ranibizumab), for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor medication.
Top